HIV+Hepatitis Policy Institute will convene a panel on Friday, April 19, 2024, at the Biomedical HIV Prevention Summit to examine how PrEP is provided today by entities including community health centers, CBOs, pharmacies, telemedicine platforms, and state health departments. We will examine how this work is financed by leveraging existing programs and systems, as well as current barriers and what can be done to close PrEP access gaps in underserved populations.
What the new section 1557 rule means for health insurance non-discrimination protections and considerations for regulators
Carl Schmid joined National Health Law Program’s Wayne Turner, Whitman Walker Institute’s Kellan Baker, and National Women’s Law Center’s Dorianne Mason to discuss what the new section 1157 rule means for health insurance non-discrimination protections at the NAIC Spring Meeting. Carl focused on provisions of the proposed rule that pertain to prescription drugs.
Copay accumulator plan designs: What life sciences manufacturers need to know heading into 2024
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, and Bill Sarraille, a partner with Sidley law, speak with Michael Harris, Mercalis’s VP of Patient Support Services Strategy, on the litigation brought by the HIV+Hepatitis Policy Institute against a federal government rule allowing insurers to not count copay assistance toward patient costs. The Court ruled in favor of patients but the government appealed and is refusing to enforce the Court’s ruling.
Legal update: Results and impact of the copay accumulator adjustment lawsuit
Carl Schmid provides an update to the NAIC on copay accumulator litigation, including the government’s recent move to appeal and seek clarification from the court and the need for state and federal enforcement that copay assistance, in most instances, must count.
Federal health policy update
Carl Schmid, along with fellow NAIC Consumer Reps, provide an update to Insurance Commissioners on federal issues including proposed changes to standard plans, , reminders to issuers against using discriminatory plan design, and an update on transparency in coverage requirements and Congressional consideration of PBM regulation.